Dosimetric and toxicity comparison between Syed-Neblett and Fletcher-Suit-Delclos Tandem and Ovoid applicators in high dose rate cervix cancer brachytherapy.

Purpose: To compare patient and tumor characteristics, dosimetry, and toxicities between interstitial Syed-Neblett and intracavitary Fletcher-Suit-Delclos Tandem and Ovoid (T&O) applicators in high dose rate (HDR) cervical cancer brachytherapy.

Methods: A retrospective analysis was performed for cervical cancer patients treated with 3D-based HDR brachytherapy from 2011 to 2023 at a single institution. Dosimetric parameters for high-risk clinical target volume and organs at risk were obtained.

Squamous Cell and Adenoid Cystic Carcinoma Collision Tumor of the Soft Palate Treated with Surface Mold Brachytherapy.

Simultaneous primary cancers are rare in the oropharynx. This report describes the first reported case of a collision tumor of squamous cell and adenoid cystic carcinoma in the soft palate. The patient was immunosuppressed with a history of liver transplantation, smoking and heavy alcohol drinking.

Negative effect of seroma on breast balloon brachytherapy dosimetry.

Purpose: Balloon brachytherapy is commonly used to deliver Accelerated Partial Breast Irradiation (APBI). Seroma interference is a relatively common phenomenon during APBI. The negative effect of seroma accumulation on the planning target volume evaluation (PTV_Eval) coverage is not well understood.

Interfraction accumulation of seroma during accelerated partial breast irradiation: preliminary results of a prospective study.

Purpose: To quantify and characterize the process of seroma accumulation during accelerated partial breast irradiation using multicatheter balloon brachytherapy.

Materials And Methods: Twenty-two patients were treated using the Contura Multilumen brachytherapy catheter to a dose of 34Gy in 10 fractions over 5 treatment days. Serial aspirations of the vacuum port of the catheter were performed at the time of CT simulation and before each treatment.

Evaluation of the dose distribution for prostate implants using various 125I and 103Pd sources.

Recently, several different models of 125I and 103Pd brachytherapy sources have been introduced in order to meet the increasing demand for prostate seed implants. These sources have different internal structures; hence, their TG-43 dosimetric parameters are not the same. In this study, the effects of the dosimetric differences among the sources on their clinical applications were evaluated.

Monte Carlo dosimetric characterization of the IsoAid ADVANTAGE 103Pd brachytherapy source.

For roughly 25 years, 125I and 103Pd sources have been used in the treatment of various malignant diseases such as prostate cancer. Various new sources have been marketed and produced to meet the demand for new sources to use in treatment. Recently, IsoAID LLC created the ADVANTAGE 103Pd source.

A Monte Carlo evaluation of the dosimetric characteristics of the EchoSeed Model 6733 (125)I brachytherapy source.

Purpose: Recently a new design of a (125)I brachytherapy source was introduced for interstitial seed implants, particularly for prostate seed implants. This new source is the EchoSeed Model 6733 (125)I brachytherapy source. Due to the differences in source design and manufacturing process from one new source to the next, their dosimetric parameters should be determined according to the American Association of Physicists in Medicine (AAPM) TG-43 guidelines.

Evaluation of the veridose QC phantom.

Daily, monthly, and annual quality control (QC) of linear accelerators are part of the major tasks of the medical physicist to verify that patients are receiving proper radiation treatment. The control tests consist of the measurement of beam output, verification of the beam energy, and determination of the beam flatness and symmetry in a linear accelerator. A new device, referred to as QC phantom, was designed and fabricated for the QC of linear accelerators.

A Monte Carlo evaluation of the dosimetric characteristics of the Best Model 2301 125I brachytherapy source.

Recently a new design of a 125I brachytherapy source was introduced for interstitial seed implants, particularly for prostate seed implants. This new source is the Best Model 2301 brachytherapy source. Due to the differences in source design and manufacturing process from one new source to the next, their dosimetric parameters should be determined according to the AAPM TG-43 guidelines.

Determination of the dosimetric characteristics of InterSource125 iodine brachytherapy source.

The TG-43 recommended dosimetric characteristics of a new 125I brachytherapy source have been experimentally and theoretically determined. The measurements were performed in Solid Water using LiF TLDs. The calculations were performed using Monte Carlo simulations in Solid Water and water.